project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9L6; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.84; concentration: 0.16; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.14; rna integrity number: 7.6; age at index: 64; days to birth: -23681; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 23681; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 687.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 733; initial weight: 520.0; sample id: f634296d-85a2-4fbd-a3c1-10a238c058f5; sample submitter id: TCGA-ZG-A9L6-01A; portion id: 9be7b52c-f3ef-4a47-8200-b5e66540be98; portion submitter id: TCGA-ZG-A9L6-01A-11; slide id: ea3a5eee-985f-4c72-a0b5-8a1d9f0c8180; slide submitter id: TCGA-ZG-A9L6-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 20.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;